Endothelial Monocyte Activating Polypeptide II inhibits lung neovascularization and airway epithelial morphogenesis

Margaret A. Schwarz, Fangrong Zhang, Sarah Gebb, Vaughn Starnes, David Warburton

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Neovascularization is crucial to lung development and is mediated through a variety of angiogenic and anti-angiogenic factors. Herein, we show that excess Endothelial Monocyte Activating Polypeptide (EMAP) II, an anti-angiogenic protein, not only inhibits fetal lung neovascularization, but also significantly alters airway epithelial morphogenesis. In a murine allograft model of lung neovascularization and morphogenesis, embryonic lungs transplanted under the skin of immunocompromised mice receiving intraperitoneal EMAP II, had a 56% reduction in vessel density (P<0.0001) compared to control. EMAP II treated lung transplants also exhibited a marked alteration in lung morphogenesis, including lack of type II alveolar cell formation, determined by markedly decreased expression of surfactant protein C, and increased apoptosis. In contrast, lung implants in animals receiving an EMAP II blocking antibody had an increase in vessel density of 50% (P<0.0001) and increased expression of surfactant protein C mRNA in distal epithelium. These studies demonstrate that EMAP II negatively modulates lung neovascularization as well as leading to the arrest of lung airway epithelial morphogenesis and apoptosis. Copyright (C) 2000 Elsevier Science Ireland Ltd.

Original languageEnglish (US)
Pages (from-to)123-132
Number of pages10
JournalMechanisms of Development
Volume95
Issue number1-2
DOIs
StatePublished - Jul 1 2000

Fingerprint

Morphogenesis
Lung
Protein C
Surface-Active Agents
Angiogenic Proteins
Apoptosis
Alveolar Epithelial Cells
small inducible cytokine subfamily E, member 1
Blocking Antibodies
Angiogenesis Inducing Agents
Allografts
Epithelium
Transplants
Messenger RNA
Skin

Keywords

  • Angiogenesis
  • Anti-angiogenesis
  • Endothelial Monocyte Activating Polypeptide II
  • Lung morphogenesis
  • Neovascularization
  • Pulmonary microvasculature

ASJC Scopus subject areas

  • Embryology
  • Developmental Biology

Cite this

Endothelial Monocyte Activating Polypeptide II inhibits lung neovascularization and airway epithelial morphogenesis. / Schwarz, Margaret A.; Zhang, Fangrong; Gebb, Sarah; Starnes, Vaughn; Warburton, David.

In: Mechanisms of Development, Vol. 95, No. 1-2, 01.07.2000, p. 123-132.

Research output: Contribution to journalArticle

Schwarz, Margaret A. ; Zhang, Fangrong ; Gebb, Sarah ; Starnes, Vaughn ; Warburton, David. / Endothelial Monocyte Activating Polypeptide II inhibits lung neovascularization and airway epithelial morphogenesis. In: Mechanisms of Development. 2000 ; Vol. 95, No. 1-2. pp. 123-132.
@article{cb32d09e85704375b029fe5cc2cdfe15,
title = "Endothelial Monocyte Activating Polypeptide II inhibits lung neovascularization and airway epithelial morphogenesis",
abstract = "Neovascularization is crucial to lung development and is mediated through a variety of angiogenic and anti-angiogenic factors. Herein, we show that excess Endothelial Monocyte Activating Polypeptide (EMAP) II, an anti-angiogenic protein, not only inhibits fetal lung neovascularization, but also significantly alters airway epithelial morphogenesis. In a murine allograft model of lung neovascularization and morphogenesis, embryonic lungs transplanted under the skin of immunocompromised mice receiving intraperitoneal EMAP II, had a 56{\%} reduction in vessel density (P<0.0001) compared to control. EMAP II treated lung transplants also exhibited a marked alteration in lung morphogenesis, including lack of type II alveolar cell formation, determined by markedly decreased expression of surfactant protein C, and increased apoptosis. In contrast, lung implants in animals receiving an EMAP II blocking antibody had an increase in vessel density of 50{\%} (P<0.0001) and increased expression of surfactant protein C mRNA in distal epithelium. These studies demonstrate that EMAP II negatively modulates lung neovascularization as well as leading to the arrest of lung airway epithelial morphogenesis and apoptosis. Copyright (C) 2000 Elsevier Science Ireland Ltd.",
keywords = "Angiogenesis, Anti-angiogenesis, Endothelial Monocyte Activating Polypeptide II, Lung morphogenesis, Neovascularization, Pulmonary microvasculature",
author = "Schwarz, {Margaret A.} and Fangrong Zhang and Sarah Gebb and Vaughn Starnes and David Warburton",
year = "2000",
month = "7",
day = "1",
doi = "10.1016/S0925-4773(00)00361-0",
language = "English (US)",
volume = "95",
pages = "123--132",
journal = "Mechanisms of Development",
issn = "0925-4773",
publisher = "Elsevier Ireland Ltd",
number = "1-2",

}

TY - JOUR

T1 - Endothelial Monocyte Activating Polypeptide II inhibits lung neovascularization and airway epithelial morphogenesis

AU - Schwarz, Margaret A.

AU - Zhang, Fangrong

AU - Gebb, Sarah

AU - Starnes, Vaughn

AU - Warburton, David

PY - 2000/7/1

Y1 - 2000/7/1

N2 - Neovascularization is crucial to lung development and is mediated through a variety of angiogenic and anti-angiogenic factors. Herein, we show that excess Endothelial Monocyte Activating Polypeptide (EMAP) II, an anti-angiogenic protein, not only inhibits fetal lung neovascularization, but also significantly alters airway epithelial morphogenesis. In a murine allograft model of lung neovascularization and morphogenesis, embryonic lungs transplanted under the skin of immunocompromised mice receiving intraperitoneal EMAP II, had a 56% reduction in vessel density (P<0.0001) compared to control. EMAP II treated lung transplants also exhibited a marked alteration in lung morphogenesis, including lack of type II alveolar cell formation, determined by markedly decreased expression of surfactant protein C, and increased apoptosis. In contrast, lung implants in animals receiving an EMAP II blocking antibody had an increase in vessel density of 50% (P<0.0001) and increased expression of surfactant protein C mRNA in distal epithelium. These studies demonstrate that EMAP II negatively modulates lung neovascularization as well as leading to the arrest of lung airway epithelial morphogenesis and apoptosis. Copyright (C) 2000 Elsevier Science Ireland Ltd.

AB - Neovascularization is crucial to lung development and is mediated through a variety of angiogenic and anti-angiogenic factors. Herein, we show that excess Endothelial Monocyte Activating Polypeptide (EMAP) II, an anti-angiogenic protein, not only inhibits fetal lung neovascularization, but also significantly alters airway epithelial morphogenesis. In a murine allograft model of lung neovascularization and morphogenesis, embryonic lungs transplanted under the skin of immunocompromised mice receiving intraperitoneal EMAP II, had a 56% reduction in vessel density (P<0.0001) compared to control. EMAP II treated lung transplants also exhibited a marked alteration in lung morphogenesis, including lack of type II alveolar cell formation, determined by markedly decreased expression of surfactant protein C, and increased apoptosis. In contrast, lung implants in animals receiving an EMAP II blocking antibody had an increase in vessel density of 50% (P<0.0001) and increased expression of surfactant protein C mRNA in distal epithelium. These studies demonstrate that EMAP II negatively modulates lung neovascularization as well as leading to the arrest of lung airway epithelial morphogenesis and apoptosis. Copyright (C) 2000 Elsevier Science Ireland Ltd.

KW - Angiogenesis

KW - Anti-angiogenesis

KW - Endothelial Monocyte Activating Polypeptide II

KW - Lung morphogenesis

KW - Neovascularization

KW - Pulmonary microvasculature

UR - http://www.scopus.com/inward/record.url?scp=0034234724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034234724&partnerID=8YFLogxK

U2 - 10.1016/S0925-4773(00)00361-0

DO - 10.1016/S0925-4773(00)00361-0

M3 - Article

C2 - 10906456

AN - SCOPUS:0034234724

VL - 95

SP - 123

EP - 132

JO - Mechanisms of Development

JF - Mechanisms of Development

SN - 0925-4773

IS - 1-2

ER -